Phospholipase A2 as a point of care alternative to serum amylase and pancreatic lipase
File(s)
Accepted version
Author(s)
Type
Journal Article
Abstract
Acute pancreatitis is a relatively common and potentially fatal condition, but the presenting symptoms are non-specific and diagnosis relies largely on the measurement of amylase activity by the hospital clinical laboratory. In this work we develop a point of care test for pancreatitis measuring concentration of secretory phospholipase A2 group IB (sPLA2-IB). Novel antibodies for sPLA2-IB were raised and used to design an ELISA and a lateral flow device (LFD) for the point of care measurement of sPLA2-IB concentration, which was compared to pancreatic amylase activity, lipase activity, and sPLA2-IB activity in 153 serum samples. 98 of these samples were obtained from the pathology unit of a major hospital and classified retrospectively according to presence or absence of pancreatitis, and the remaining 55 were obtained from commercial sources to serve as high lipase (n = 20), CA19-9 positive (n = 15), and healthy (n = 20) controls. sPLA2-IB concentration correlated well with the serum activity of both amylase and lipase, and performed at least as well as either markers in the differentiation of pancreatitis from controls.
Date Issued
2016-06-21
Date Acceptance
2016-05-11
Citation
Nanoscale, 2016, 8, pp.11834-11839
ISSN
2040-3372
Publisher
Royal Society of Chemistry
Start Page
11834
End Page
11839
Journal / Book Title
Nanoscale
Volume
8
Copyright Statement
© The Royal Society of Chemistry 2016
Sponsor
Engineering & Physical Science Research Council (E
Identifier
http://www.ncbi.nlm.nih.gov/pubmed/27228183
Grant Number
EP/K502352/1
Subjects
Nanoscience & Nanotechnology
10 Technology
02 Physical Sciences
03 Chemical Sciences
Publication Status
Published
Date Publish Online
2016-05-17